Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Active not recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Carcinoma, Non-Small-Cell Lung 56Lung Neoplasms 29Triple Negative Breast Neoplasms 13Breast Neoplasms 13Ovarian Neoplasms 12Endometrial Neoplasms 12Squamous Cell Carcinoma of Head and Neck 11Small Cell Lung Carcinoma 11Parkinson Disease 4, Autosomal Dominant Lewy Body 11Neoplasms 10Fallopian Tube Neoplasms 10Neoplasm Metastasis 8Colorectal Neoplasms 5Adenocarcinoma of Lung 5Carcinoma 4Pancreatic Neoplasms 3Oropharyngeal Neoplasms 3Melanoma 3Lung Diseases 3Esophageal Neoplasms 3Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Thoracic Neoplasms 2Sarcoma 2Respiratory Tract Neoplasms 2Respiratory Tract Diseases 2Rectal Neoplasms 2Prostatic Neoplasms 2Pathologic Complete Response 2Non-squamous Non-small Cell Lung Cancer 2

Interventions

Gemcitabine 11Magnetic Resonance Spectroscopy 10Specimen Handling 8Cisplatin 7pembrolizumab 6Radiation 5Mitomycin 4Fluorouracil 4Cystoscopy 4enfortumab vedotin 3durvalumab 3dehydroftorafur 3avelumab 3Transurethral Resection of Bladder 3Radiotherapy 3Platinum 3Nivolumab 3Mitozytrex 3Cystectomy 31,2-diaminocyclohexaneplatinum II citrate 3ulixertinib 2tremelimumab 2erdafitinib 2atezolizumab 2Paclitaxel 2Immunoglobulin G 2Docetaxel 2Disulfides 2Carboplatin 2Biopsy 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Urinary Bladder Neoplasms × Carboplatin × 30 days × Clear all
NCT03682068 2026-05-28

NILE

AstraZeneca

Phase 3 Active not recruiting
1,246 enrolled
Genitourinary

Urinary Bladder Neoplasms

NCT06225596 2026-05-27

Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)

BicycleTx Limited

Phase 2 Active not recruiting
375 enrolled
Genitourinary

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡